替罗非班在体外对P-选择素、白介素-6、白介素-1β的影响

中国临床药理学与治疗学 ›› 2010, Vol. 15 ›› Issue (7): 732-736.

替罗非班在体外对P-选择素、白介素-6、白介素-1β的影响

谢双锋¹, 尹松梅¹, 聂大年¹, 李益清¹, 肖洁¹, 马丽萍¹, 王秀菊¹, 王景峰²

¹中山大学附属第二医院血液内科, ²心内科,广州 510120,广东

收稿日期:2010-03-04 修回日期:2010-06-24 出版日期:2010-07-26 发布日期:2020-09-15
作者简介:谢双锋,男,博士,主治医师,研究方向:血栓病和血小板功能。Tel:020-81332486 E-mail:xiesf@163.com
基金资助:
广东省医学科研基金(B2007056)

Effect of tirofiban on the plasma inflammatory factors of P-selectin,IL-6 and IL-1β in vitro

XIE Shuang-feng¹, YIN Song-mei¹, NIE Da-nian¹, LI Yi-qing¹, XIAO Jie¹, MA Li-ping¹, WANG Xiu-ju¹, WANG Jing-feng²

¹Department of Hematology, ²Department of Cardiology, Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong, China

Received:2010-03-04 Revised:2010-06-24 Online:2010-07-26 Published:2020-09-15

摘要/Abstract

摘要： 目的: 探讨血小板膜糖蛋白(GP)Ⅱb/Ⅲa受体拮抗剂替罗非班在体外对血浆炎症因子的影响,为合理应用血小板GPⅡb/Ⅲa受体拮抗剂提供理论依据。方法: 以二磷酸腺苷(ADP)或凝血酶为诱聚剂在体外激活血小板,同时加入20%、50%和80%抑制浓度的替罗非班,37 ℃共同孵育30 min,标本离心,取上清液用ELISA法检测P-选择素和IL-6、IL-1β等炎症因子的改变。结果: ADP(终浓度为 10 μmol/L)可诱导P-选择素增多;此效应能被31.25 μmol/L(IC₂₀)以上浓度的替罗非班抑制;ADP对IL-6、IL-1β的产生无影响。凝血酶(终浓度 0.03 U/L)可诱导P-选择素、IL-6、IL-1β产生增多;此效应能被 156.25 μmol/L(IC₅₀)以上浓度的替罗非班抑制。各浓度替罗非班单独应用对P-选择素、IL-6、IL-1β均无影响。结论: 替罗非班浓度在IC₅₀以上时可抑制凝血酶诱导的P-选择素和炎症因子增多。充足剂量的替罗非班在体外有抑制血小板活化和炎症反应的双重效应。

关键词: 血小板, 替罗非班, 炎症因子

Abstract: AIM: To explore the anti-inflammatory effects of tirofiban in vitro, and to provide the theoretical basis for properly using the GP Ⅱb/Ⅲa receptor antagonists.METHODS: The platelets in the blood samples were activated in vitro with adenosine diphosphate (ADP) or thrombin respectively. Tirofiban was added to each sample in 20%, 50% or 80% inhibiting concentrations. Then the mixed liquor was incubated in 37 ℃ for 30 minutes. After centrifugation, the samples were divided to supernatants and sediments. The P-selectin, interleukin-6 (IL-6) and interleukin-1β (IL-1β) of were detected by enzyme linked immunosorbent assay (ELISA).RESULTS: ADP (final concentration: 10 μmol/L) could induce the production of P-selectin, that could be inhibited by tirofiban in concentrations higher than 31.25 μmol/L (IC₂₀). ADP had no effect on the production of IL-6 or IL-1β. Thrombin (final concentration: 0.03 U/L) could induce the production of P-selectin, IL-6 and IL-1β, those could be inhibited by tirofiban in concentrations higher than 156.25 μmol/L (IC₅₀). Tirofiban without ADP or thrombin had no effect on the production of P-selectin, IL-6 or IL-1β.CONCLUSION: Tirofiban in concentration higher than IC₅₀ could inhibit the production of P-selectin and inflammatory factors induced by thrombin. Tirofiban in full dosage could inhibit the activation of platelet and decrease the production of inflammatory factors at the same time in vitro.

Key words: Platelet, Tirofiban, Inflammatory factor

中图分类号:

R331.1

谢双锋, 尹松梅, 聂大年, 李益清, 肖洁, 马丽萍, 王秀菊, 王景峰. 替罗非班在体外对P-选择素、白介素-6、白介素-1β的影响[J]. 中国临床药理学与治疗学, 2010, 15(7): 732-736.

XIE Shuang-feng, YIN Song-mei, NIE Da-nian, LI Yi-qing, XIAO Jie, MA Li-ping, WANG Xiu-ju, WANG Jing-feng. Effect of tirofiban on the plasma inflammatory factors of P-selectin,IL-6 and IL-1β in vitro[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(7): 732-736.

参考文献

[1] 吴进寿, 洪华山. 高血压与炎症关系的研究进展 [J]. 中国临床药理学与治疗学, 2006,11(2): 136-140.
[2] Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation [J]. Arterioscler Thromb Vasc Biol, 2009,29(7): 983-991.
[3] Libby P, Simon DI. Inflammation and thrombosis: the clot thickens [J]. Circulation, 2001,103(13): 1718-1720.
[4] Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation [J]. Trends Mol Med, 2004,10(4): 171-178.
[5] Davi G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration [J]. Circulation, 2003,107(25): 3199-3203.
[6] Pignatelli P, De Biase L, Lenti L, et al. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure [J]. Blood,2005, 106(6): 1992-1994.
[7] Bar J, Zosmer A, Hod M, et al. Changes in the effects of interleukin-1beta and tumor necrosis factor-alpha on platelet activation in early pregnancy [J]. Platelets, 2001,12(8): 453-455.
[8] Obara Y, Kurose H, Nakahata N. Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells [J]. Mol Pharmacol, 2005, 68(3): 670-679.
[9] Shiokoshi T, Ohsaki Y, Kawabe J, et al. Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells [J]. J Hypertens, 2002, 20(3): 455-461.
[10] 谢双锋, 尹松梅, 杨国雷, 等. 血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂RGDS对血小板释放反应的影响 [J]. 中山大学学报:医学科学版, 2007,28(2): 192-195.
[11] Iwaki T, Sandoval-Cooper MJ, Brechmann M, et al. A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice [J]. Blood,2006,107(10): 3883-3891.
[12] Grainger DJ, McWilliam NA, Baglin TP, et al. Suppressing thrombin generation is compatible with the development of atherosclerosis in mice [J]. Thromb Res, 2001,102(1): 71-80.
[13] Lentz SR, Miller FJ, Jr. Piegors DJ, et al. Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys [J]. Circulation, 2002,106(7): 842-846.

[1]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[2]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	李若柠, 郭展立, 王媛, 孙建军. 血小板内皮聚集受体1及其介导的信号通路在血小板和内皮细胞中的作用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 438-444.
[5]	李军民, 牛恒立, 谢明全, 苏金龙. 山楂黄酮抗动脉粥样硬化及降血脂作用机制研究[J]. 中国临床药理学与治疗学, 2023, 28(3): 276-282.
[6]	黄玉荣, 张红强, 游蓉丽, 贾颖, 王艳, 樊杰, 王颖莉. 青黛散外用凝胶对特异性皮炎小鼠的改善作用研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 19-28.
[7]	孙莹, 余勤. 凝血纤溶系统失衡与特发性肺间质纤维化发病机制及治疗的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(6): 689-695.
[8]	高家荣, 施苗苗, 陈浩, 姜辉, 秦秀娟. 芪藤消浊颗粒介导miR-339-5p对慢性肾小球肾炎大鼠炎症指标的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 457-465.
[9]	常书福. 冠心病药物治疗进展[J]. 中国临床药理学与治疗学, 2022, 27(4): 405-408.
[10]	王瑞杰, 王亮, 徐丹, 周淼淼, 李纪明. PCSK9抑制剂对冠心病患者血脂及炎症因子的影响[J]. 中国临床药理学与治疗学, 2022, 27(4): 409-417.
[11]	卢希娅, 李玉星, 李文智, 彭园园, 胡宜, 万李, 陈碧莲. 老年医学科冠心病患者抗血小板药物服用情况的调查分析[J]. 中国临床药理学与治疗学, 2022, 27(11): 1285-1291.
[12]	何秀娟, 马慧可, 刘青武, 陈佳, 林燕, 李萍. 细胞因子在创面修复中的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 579-585.
[13]	岳昭蓉, 谢飞, 王欣, 李红玉. 脾多肽注射液对治疗原发性血小板减少症的作用途径研究[J]. 中国临床药理学与治疗学, 2021, 26(11): 1229-1236.
[14]	杨慧芳, 罗颖, 赵莉. 右美托咪定对脓毒症大鼠肾功能及血清炎症因子的影响[J]. 中国临床药理学与治疗学, 2020, 25(8): 857-861.
[15]	彭静, 刘俊, 许慧芳, 李越然, 江佳, 汪盛, 周德喜, 朱艳虹, 杨魁, 栾家杰. 细胞色素P4502C19基因多态性及代谢型与ADP诱导的血小板聚集抑制率及氯吡格雷抵抗的关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(7): 746-751.